top
Search terms
Results 1 - 6 of 6 - ordered by :
Ehjcvp

Despite treatments for secondary prevention, patients with prior myocardial infarction (MI) remain at high risk for recurrent thrombotic events.1 The addition of a P2Y12 receptor antagonist to ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIAL, Giulia Magnani, Marc P. Bonaca, Marc S. Sabatine

Date : 01/10/2015 Item size : 188203 bytes
Ehjcvp

The decreased risk of AF remained significant after adjusting for age, sex, and comorbidities with a hazard ratio (95% CI) of 0.76 (0.571.00), P0.047 associated with TZD treatment compared with other ...

European Heart Journal - Cardiovascular Pharmacotherapy, Original Article, Jannik Langtved Pallisgaard, Tommi Bo Lindhardt, Laila Staerk, Jonas Bjerring Olesen, Christian Torp-Pedersen, Morten Lock ...

Date : 08/11/2016 Item size : 223886 bytes
Ehjcvp

Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used drugs, but much attention has been focused on the relationship of these drugs to cardiovascular conditions.1 In this issue of European ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIALS, Marco Proietti, Gregory Y.H. Lip

Date : 01/04/2015 Item size : 163809 bytes
Ehjcvp

Abstract Aortic valve stenosis (AVS) is associated with significant morbidity and mortality, especially in the presence of symptoms and echocardiographic signs of left ventricular remodelling (i.e. ...

European Heart Journal - Cardiovascular Pharmacotherapy, Review, Charlotte Andersson, Jawdat Abdulla

Date : 01/01/2017 Item size : 230402 bytes
Ehjcvp

Abstract Aortic valve stenosis (AVS) is associated with significant morbidity and mortality, especially in the presence of symptoms and echocardiographic signs of left ventricular remodelling (i.e. ...

European Heart Journal - Cardiovascular Pharmacotherapy, Review, Charlotte Andersson, Jawdat Abdulla

Date : 11/09/2016
Ehjcvp

Glycoprotein IIb/IIIa receptor inhibitors (GPIs) block the final common pathway leading to platelet aggregation that occurs via the cross-linking of fibrinogen and von Willebrand factor upon exposure ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLES, Jeffrey D. Wessler, Robert P. Giugliano

Date : 01/04/2015